BrainChild Bio gets $116M for pivotal trial of pediatric brain tumor CAR-Tnews2026-09-08T11:00:53+00:00September 8th, 2026|Endpoints News|
Diabetes cell therapy biotechs Sernova and Seraxis to mergenews2026-09-08T11:00:21+00:00September 8th, 2026|Endpoints News|
#ERS26: Roivant reports Phase 2 win for lung disease drug that it got from Bayernews2026-09-08T10:00:00+00:00September 8th, 2026|Endpoints News|
#ERS26: Beam says AATD base editing data hold up after one yearnews2026-09-08T08:30:35+00:00September 8th, 2026|Endpoints News|
Updated: Novartis sinks after second disastrous trial failure, this time of Avidity-acquired drugnews2026-09-08T08:24:44+00:00September 8th, 2026|Endpoints News|
FDA approves AstraZeneca’s oral SERD for breast cancer despite negative adcomm votenews2026-09-07T17:17:43+00:00September 7th, 2026|Endpoints News|
Novartis’ Phase 3 pelacarsen study miss raises the stakes for Amgen, Lillynews2026-09-07T14:48:28+00:00September 7th, 2026|Endpoints News|
Updated: Novo Nordisk cans 2 more trials of IL-6 heart drug for futilitynews2026-09-07T07:53:43+00:00September 7th, 2026|Endpoints News|
Claret says its latest fund will have larger focus on European life sciences news2026-09-07T05:00:06+00:00September 7th, 2026|Endpoints News|
CAR-T deaths prompt halt by Novartis; Eli Lilly’s 13th acquisition of 2026; and more news2026-09-05T10:00:45+00:00September 5th, 2026|Endpoints News|
